Changes in Beneficial Ownership · 4
Rallybio Corporation
RLYBNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-11-04
- Issuer
- Rallybio Corp
- Issuer CIK
- 0001739410
- Trading symbol
- RLYB
Reporting owner 1
- Name
- HUNT RONALD
- Reporting owner CIK
- 0001247851
- Relationship
- Director
- Address
- C/O RALLYBIO CORPORATION, PO BOX 325, EAST BERLIN, CT, 06023
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-11-04 | M · Form 4 | 14,305 | A | 4.45 | 29,125 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (Right to Buy) | 4.45 | 2026-11-04 | M · Form 4 | 14,305 | D | 3.60[F2] | [F1] | 2036-02-18 | Common Stock | 14,305 | 0 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- The option is granted under the Company's 2021 Equity Incentive Plan. On October 26, 2026, the vesting of the option was accelerated in full, and the option became fully vested and exercisable as of that date.↩ 1
- F2
- This option was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $51,500.↩ 1
Signature 1
- Signed
- By: /s/ Jonathan Lieber, Attorney-in-Fact
- Date
- 2026-11-05
Company context
Rallybio (Nasdaq: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of complement dysregulation and hematology.